New acquisition has goal of developing laser-based cancer proton therapy system

HIL Applied Medical has acquired Nanolabz, which develops and fabricates smart targets for laser-based proton acceleration.

Proton therapy systems developer HIL Applied Medical (Jerusalem, Israel) has acquired Nanolabz (Reno, NV), which develops and fabricates smart targets for laser-based proton acceleration. HIL Applied Medical is developing a new class of ultra-compact, high-performance proton beam therapy systems for cancer based on high-intensity lasers and nano-engineered smart targetry.

Related: Terawatt laser enables higher energies for particle acceleration in cancer therapy

A proton beam is a form of focused radiation used to treat solid tumors. When compared to traditional radiation therapy (x-ray or photons), it reduces damage to surrounding healthy tissue by 2-6X, thereby reducing toxicities and improving patient survival and quality of life. Proton therapy is used routinely for treating many types of cancer—it is FDA-cleared and reimbursed by both federal and private insurers.

For more information, please visit www.hilappliedmedical.com.

More in Biophotonics Tools